Publications by authors named "Mitchell Nambu"

Claim this Profile
A
A calcineurin antifungal strategy with analogs of FK506.
Mitchell Nambu, Jonathan A Covel, Mili Kapoor, Xiaoming Li, Molly K Moloney

Bioorg Med Chem Lett· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lessons from (S)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an inhibitor of receptor tyrosine kinase c-Met with high protein kinase selectivity but broad phosphodiesterase family inhibition leading to myocardial degeneration in rats.
J Jean Cui, Hong Shen, Michelle Tran-Dubé, Mitchell Nambu, Michele McTigue

J Med Chem· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer.
J Jean Cui, Michele McTigue, Mitchell Nambu, Michelle Tran-Dubé, Mason Pairish

J Med Chem· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).
J Jean Cui, Michelle Tran-Dubé, Hong Shen, Mitchell Nambu, Pei-Pei Kung

J Med Chem· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
4
4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors.
Kevin K-C Liu, Shubha Bagrodia, Simon Bailey, Hengmiao Cheng, Hui Chen, Mitchell D Nambu

Bioorg Med Chem Lett· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.
Helen Y Zou, Qiuhua Li, Joseph H Lee, Maria E Arango, Scott R McDonnell, Mitchell D Nambu

Cancer Res· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis